Coastal Bridge Advisors’s Mineralys Therapeutics MLYS Stock Holding History

Coastal Bridge Advisors’s Portfolio MLYS Stock Details MLYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$66.1K	Buy	+2,450	New	+$67.2K	﹤0.01%	462

Other funds holding MLYS

Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Coastal Bridge Advisors's MLYS Position: Q2 2026 in Review

Coastal Bridge Advisors opened a new position in Mineralys Therapeutics (MLYS) in Q2 2026: 2,450 shares worth $66.1K. The stake represents ﹤0.01% of the portfolio and ranks #462 among its holdings.

224 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

Coastal Bridge Advisors held 2,450 shares of Mineralys Therapeutics worth $66.1K as of Q2 2026.
Mineralys Therapeutics was a new Coastal Bridge Advisors position in Q2 2026.
Mineralys Therapeutics made up ﹤0.01% of Coastal Bridge Advisors's portfolio in Q2 2026, its #462 holding.
224 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Coastal Bridge Advisors's 13F filing for Q2 2026, filed 17 Aug 2026.